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Kallikrein and prekallikrein of the isolated basolateral membrane of rat
kidney. A basolateral membrane (BLM) enriched fraction of the homog-
enized rat kidney contained kallikrein and prekallikrein which differ
from urinary kallikrein. Triton X-100 (0.1%) or melittin (1 o— — 10 M)
solubilized the membrane-bound enzyme. Prekallikrein was activated
by trypsin and plasmin. Active kallikrein and activated prekallikrein
cleaved the chromogenic substrate S-2266 and released bradykinin from
kininogen. Aprotinin and antiserum to rat urinary kallikrein inhibited
BLM kallikrein. Gel electrophoresis separated activated BLM prekal-
likrein and kallikrein; prekallikrein even after activation moved slower
(Rf = 0.3) in electrophoresis at an alkaline pH than active kallikrein (Rf
= I). Gel filtration resolved BLM kallikrein to two proteins of low (4 x
i0 M) and high (1.5 x lO M) molecular weight. After isoelectric
focusing of the activated BLM fraction, two kallikreins with pls of 3.9
and 5.3 were obtained. The BLM fraction also contained renin which
became active after Triton treatment. Renin activity was not enhanced
by trypsin or acid pH indicating that there was no prorenin present.
Thus, BLM of rat kidney contains a kallikrein which is different from
urinary kallikrein. This kallikrein, when released from basal membrane,
may appear in renal lymph and venous effluent.
Kallikréine et prékallikreine dans les membranes basolatérales isolëes
de reins de rat. Une fraction enrichie en membranes basolatérales
(BLM) de reins homogéneisés de rat contenait une kallikréine et une
prékallikrëine différentes de Ia kallikréine urinaire. Le Triton X-l00
(0,1%) et Ia mélittine (l0— — l0 M) solubilisaient l'enzyme liée aux
membranes. La prékallikréine était activée par Ia trypsine et par la
plasmine. La kallikréine active et Ia prékallikréine activëe clivaient le
substrat chromogene S-2266 et libéraient de Ia bradykinine a partir du
kininogene. L'aprotinine et un antiserum contre Ia kallikrëine urinaire
de rat inhibaient Ia kallikréine des BLM. L'électrophorese sur gel a
permis de separer Ia prékallikréine activée de BLM et Ia kallikréine; Ia
prékallikréine migrait plus lentement (Rf 0,3) méme aprCs activation
en electrophorèse a un pH alcalin que Ia kallikréine active (Rf = I). La
filtration sur gel a separé Ia kallikréine de BLM en deux protéines de
faible (4 x l0 M) et de fort (1,5 x JØ5 M) poids moléculaires. Après
focalisation isoelectrique de Ia fraction activée de BLM, deux kalli-
kréines de p1 3,9 et 5,8 ont été obtenues. La fraction de BLM contenait
egalement de Ia rénine qui devenait active après traitement au Triton.
L'activité rénine n'était pas stimulée par Ia trypsine ni par un pH acide,
indiquant qu'il n'y avait pas de prorénine présente. Ainsi les BLM de
reins de rat contiennent une kallikréine différente de Ia kallikrCine
urinaire. Cette kallikréine, lorsqu'elle est relarguée des membranes
basales, pourrait apparaitre dans Ia lymphe et I'effluent veineux rénaux.
Kallikrein excretion in urine has been studied by many
investigators whose interest stems partly from reports that
aldosterone increases and some forms of hypertension decrease
the kallikrein level in urine [1, 2]. Four strains of genetically
hypertensive rats excrete less than normal amounts of kallikrein
[21. The influence of kallikrein on blood pressure is complex
and presumably involves several different mechanisms. Kalli-
krein is also released into the lymph [3] and venous effluent
from the kidney [4], a process enhanced by vasoactive agents.
Renal kallikrein was described to decrease renal vascular
resistance [5, 6]. Kallikrein can liberate renin from kidney slices
[7] and is a putative activator of a prorenin [8, 9]. Kinins,
products of kallikrein action, are present in urine [10, 11] and
release prostaglandins at low concentrations [12, 13].
Although it is very likely that most of the active kallikrein in
urine originates from the kidney, there are far fewer studies on
the renal enzyme than on urinary kallikrein. It was established
that renal kallikrein is a plasma membrane-bound enzyme [14,
151 that enters the nephron at the level of the distal tubules [16],
but these facts alone cannot explain the variety of actions
attributed to renal kallikrein. Thus, we investigated the subcel-
lular distribution of rat renal kallikrein [17, 18] and isolated
membrane fractions from the homogenized rat kidney contain-
ing kallikrein and prekallikrein [19].
One fraction was enriched in plasma membrane (PM) and
presumably contains fragments of the apical tubular membrane
[17, 18]. This communication shows that a basolateral mem-
brane (BLM)-enriched fraction of the rat kidney contains an
active kallikrein and a prekallikrein, which when activated have
properties different from those of urinary kallikrein and PM
kallikrein.
Methods
Materials. S-2266 was purchased from Kabi of Stockholm
and plasmin (from porcine blood 0.4 casein U/mg) and melittin
from Sigma, St. Louis, Missouri. Molecular weight marker
proteins and Sephadex G-200 were from Parmacia, Piscataway,
New Jersey. Antisera to rat urinary kallikrein and bradykinin
were donated by Drs. 0. A. Carretero, Detroit, Michigan; H. S.
Margolius, Charleston, South Carolina; and F. Alhenc-Gelas,
Paris, France; and aprotinin by Dr. G. Haberland of Bayer AG.
Pooled rat urine was the source of urinary kallikrein. Heated
dog and rat plasma were used for kininogen.
Preparation of fractions. Rat renal cortical BLM was pre-
pared from homogenized rat kidney cortex by differential
centrifugation in buffered sucrose, which included 18 steps of
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washing the precipitates [19, 201. Briefly, the homogenate was
centrifuged first at x200g then at x2,000g in buffered sucrose
containing 0.5 mM calcium chloride. The precipitate was
washed and recentrifuged ten times. Then discontinuous su-
crose density gradient centrifugation was employed to obtain a
fraction at 1.16 < d < 1.18 (glml) which, after repeated
centrifugation, was washed with hypo- and isotonic solutions.
Enzymes in washed BLM-enriched fraction were solubilized by
incubation in 0.1% Triton X-100 for 30 mm at 4° C and then
centrifuged at x 105,000g for 60 mm, in buffered (pH 7.4) 0.25 M
sucrose. The supernatant was the source of kallikrein and
prekallikrein. The effect of melittin on BLM kallikrein was
studied under the same conditions except Triton was replaced
by melittin and a 1-mm x8,000g centrifugation was used after
the incubation period. A fraction enriched in apical membrane
fragments (PM) was obtained after homogenization and centrif-
ugation according to Nishimura, Ward, and Erdös and Nishi-
mura et al [17, 181. The relative specific activity of Nat, Kt
ATPase in the BLM fraction was enriched 7.2-fold over the
crude homogenate although that of alkaline phosphatase de-
creased to 0.45 [191. The relative specific activity of alkaline
phosphatase increased 11-fold in the PM-fraction [18, 191. The
ratio of Nat, K-ATPase to Mg2-ATPase in the BLM fraction
was 2.6, while it was 0.22 in the PM fraction [191. Freeze
fracture images of the isolated BLM fraction showed multiple
sheets of large membrane fragments and structures that resem-
bled basal plasma membrane infoldings seen in distal tubules
[19].
Activation of prekallikrein. Prekallikrein obtained from the
solubilized BLM, or eluted after gel electrophoresis or gel
filtration was incubated routinely with 10 jg of trypsin or an
equivalent activity of Sepharose 4B-bound trypsin, [191 or with
10 g of plasmin at room temperature in 10 mrvi Tris.HCI, pH
7.4. The tubes were rotated on a turntable and after an
incubation of usually 60 mm (with soluble trypsin or plasmin),
20 g of soybean trypsin inhibitor or 200 rg of lima bean trypsin
inhibitor was added to stop the reaction. This amount of
inhibitor completely prevented trypsin or plasmin activities.
Samples incubated with bound trypsin were centrifuged imme-
diately at 250 g for 3 mm, and kallikrein activity was measured
in the supernatant. No trypsin activity was detected in the
supernatant after the Sepharose 4B-bound trypsin was sedi-
mented. The specificity of activated kallikrein was shown by
incubating BLM and trypsin- or plasmin-treated BLM with
antiserum to rat urinary kallikrein for 2 hr at 4° C or with
aprotinin (50 U) for 30 mm at room temperature.
The activity of kallikrein was measured with D-Val-Leu-Arg-
p-nitroanilide (S-2266) as substrate [17, 18, 21] in 0.1 M Hepes
buffer of pH 9.1 in a recording spectrophotometer or by
determining the amount of kinin released from heated dog or rat
plasma by radioimmunoassay [17]. The activity of trypsin and
plasmin added to activate prekallikrein was assessed with S-
2266 substrate.
Chromatography of kinins. To characterize the kinin released
by BLM kallikrein and trypsin-activated BLM prekallikrein,
the reaction mixture of the kinin generating system contained
i0 M o-phenanthroline, 5 x lO M EDTA and 10-6 M SQ-
14225 (captopril) as kininase inhibitors and heated dog plasma
or rat plasma as substrate in 0.1 M Tris.HCI, pH 8.5. This
mixture was incubated for 30 mm at 37° C; the reaction was
stopped with ethanol and then dried at 50° to 60° C under
nitrogen. The dried extract was dissolved in buffer and applied
to a CM-cellulose column (0.9 cm x 11 cm). CM-cellulose
column chromatography was carried out according to Seki,
Nakajama, and Erdös [22], except that elution buffer contained
0.2 g/liter of lysozyme, and a radioimmunoassay was used to
determine the amount of kinin released. The recovery of
synthetic bradykinin and kallidin (10 ng added as standards)
was 85 and 80% in separate peaks. A conversion of kallidin to
bradykinin by aminopeptidases was not observed [23].
Preparative polyacrylamide gel electrophoresis. Gel electro-
phoresis was performed in 5% polyacrylamide gels [17, 181 with
a current of 2.5 mA per tube for 2 hr. The gels were cut to 2-mm
wide segments and proteins were eluted from gels with 50 mM
Tris, pH 8.9. Trypsin or plasmin was added to the eluate to
localize prekallikrein activity as described above. Active kalli-
krein was measured with S-2266 substrate and by determining
the amount of kinin released by radioimmunoassay.
Isoelectric focusing. Isoelectric focusing in 5% polyacryl-
amide gels was carried out according to Dale and Latner [24,
25]. Proteins were dissolved in the gel solution and poured into
gel tubes. Isoelectric focusing of the fractions proceeded under
a constant potential of 100 V at 4° C for 16 hr. The gels were cut
into segments, and proteins were eluted from gels with 0.1 M
Tris.HCI, pH 8.5. One part of each eluate was used for
measurement of kallikrein activity (kininogenase activity) and
another part to assay prekallikrein after trypsin or plasmin
treatment.
Gel filtration. The molecular weight of rat kidney cortical
prekallikrein and kallikrein was estimated on a Sephadex G-200
column (2.6 cm x 43 cm). Gel filtration was carried out at a flow
rate of 12 ml/hr with 0.05 M Tris, pH 7.4, containing 0.1 M
sodium chloride and 0.1% Triton X-lOO. Fractions of 2.8 ml
were collected. After measuring the absorption of proteins at
280 nm, each fraction was concentrated to 1 ml by ultrafiltration
on a YM-lO Amicon membrane. One part of each concentrated
eluate was used for measurement of kallikrein activity with S-
2266 and another part was used to assay prekallikrein after
trypsin treatment. The column was calibrated with the follow-
ing molecular weight standards under the experimental condi-
tions described: (1) thyroglobulin (669,000), (2) catalase
(232,000), (3) bovine albumin (67,000), (4) crude rat urinary
kallikrein (39,000), and (5) chymotrypsinogen A (25,000).
Renin. Renin activity was determined by radioimmunoassay
of angiotensin I released from nephrectomized rat plasma [181
in the presence of 3 >< i03 M EDTA, 1 x i03 M 0-
phenanthroline, and 1.5 x 10 M dimercaptopropanol in 0.24 M
Tris, pH 7.5.
Results
Activation of prekallikrein. The BLM-enriched fraction con-
tained both an active kallikrein and a prekallikrein in mem-
brane-bound form which were released from the membrane by
0.1% Triton X-100. Figures 1 and 2 show the activation of
prekallikrein in the soluble fraction by free and Sepharose-
bound trypsin and plasmin. Figure 1 shows that both the
kininogenase activity and the rate of hydrolysis of S-2266 were
enhanced in a parallel manner by trypsin indicating the conver-
sion of a prekallikrein to kallikrein in the soluble fraction.
Figure 2 shows that plasmin also enhanced S-2266 hydrolysis
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Fig. 1. Activation of prekallikrein from the BLM-enriched fraction of
the homogenized rat kidney by soluble (A and LI) and Sepharose-bound
trypsin (A and I). Abscissa represents micrograms of trypsin. Ordi-
nates represent nanograms of bradykinin released, determined by
radioimmunoassay (A—A:A—A) and nanomoles of S-2266 hydrolyzed
(LI—LI:•—U). Vertical lines are SEM.
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Fig. 2. Activation of prekallikrein from the BLM-enriched fraction of
the homogenized rat kidney by hog plasmin. Abscissa represents
plasmin activity in milliunits. Ordinates represent nanograms of brady-
kinin released (0—0) and nanomoles of S-2266 hydrolyzed (•—•).
Vertical lines are SEM.
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Fig. 4. Release of bradykinin from kininogen by BLM kallikrein (—) and
by activated BLM prekallikrein (---) determined by ion-exchange chro-
matography on a CM-cellulose column. Abscissa represents the num-
ber of fractions collected and marking of the positions of eluted
synthetic bradykinin (first peak) and kallidin (second peak). Ordinates
represent ammonium formate concentration and nanograms of kinin
collected.
(not shown). Aprotinin inhibited BLM kallikrein and trypsin-
activated prekallikrein indentically. Ten units of aprotinin in-
hibited 86% of the kininogenase activity and 50 U inhibited it by
95%.
Kinin release. When BLM kallikrein and activated BLM
prekallikrein were incubated with heated rat or dog plasma they
released a kinin which was separated on a CM-cellulose column
and eluted with ammonium formate in the same fraction as
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Fig. 3. Inhibition of PM kallikrein (LI), BLMprekallikrein activated with
trypsin (X), and BLM kallikrein (•) by antiserum to rat urinary
kallikrein. Preimmune serum is represented by 0. Abscissa represents
dilution of antisera. Ordinate represents the percent of activity as
determined by radioimmunoassay of kinin released.
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and kininogenase activity in the solubilized BLM fraction.
Melittin also released an active kallikrein from the BLM-
enriched fraction but at a much lower concentration than
Triton. The kininogenase activity increased to 13, 240, and
483% at iO, 106, and i05 M melittin concentrations,
respectively.
Inhibition. Both kallikrein and trypsin-activated prekallikrein
were inhibited by antiserum to rat urinary kallikrein and by
aprotinin (trasylol). Kallikrein and prekallikrein were solubi-
lized with a detergent prior to adding antibody because kalli-
krein in membrane-bound form does not react with highly
diluted antiserum [17]. Figure 3 shows that the kininogenase
activity of BLM kallikrein, trypsin-activated BLM prekalli-
krein, and kallikrein from PM-enriched fraction were inhibited
at 1:22,000 to 1:90,000 dilutions of antiserum. BLM kallikrein
was inhibited at slightly lower concentrations of antibody than
the trypsin-activated enzyme. The antiserum at this dilution
also completely blocked the activity of rat urinary kallikrein
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synthetic bradykinin (Fig. 4). No conversion of added synthetic
kallidin (Lys-bradykinin) to bradykinin by aminopeptidases
occurred in the presence of the peptidase inhibitors. Bradykinin
was eluted with about 0.15 M, while kallidin appeared with 0.28
M ammonium formate.
Gel electrophoresis. Solubilized active BLM kallikrein in
preparative polyacrylamide gel electophoresis migrated with
the front at pH 8.9 with Rf = 1 (Fig. 5A). PM and urinary
kallikrein migrate similarly at that pH l7, 18]. When the protein
fractions were eluted from the gel slices and treated with
trypsin, kallikrein activity was found at the origin in the first
fraction, thus prekallikrein did not migrate at pH 8.9. Electro-
phoresis of activated prekallikrein revealed that the trypsin
activated prekallikrein and active kallikrein from the BLM
fraction migrated differently. Activated prekallikrein had an Rf
value of 0.3 clearly differing from that of active kallikrein (or
urinary and PM kallikrein) [17] which migrated with the front
(Fig. SB). Antiserum to rat urinary kallikrein and 50 U of
aprotinin inhibited the kallikrein activity generated by trypsin.
Gel filtration. The molecular weight of kallikrein and prekal-
likrein in the final supernatant of the BLM fraction (see
Methods) was estimated by gel filtration on Sephadex G-200
columns. The active soluble BLM kallikrein in the presence of
0.1% Triton appeared in a peak corresponding to an estimated
molecular weight of 4 x l0 which was identical with that of
urinary kallikrein and PM kallikrein (Fig. 6A). Treating the
fractions collected after gel filtration with trypsin revealed the
presence of prekallikrein in a fraction which eluted at an
estimated molecular weight of 1.5 x 1O5 (Fig. 6B). When
trypsin-activated BLM was subjected to the same type of gel
filtration, two active peaks were recovered (peaks 2 and 3 in
Fig. 6. Sephadex G-200 gel filtration of prekallikrein (1), active kalli-
krein (2), and prekallikrein activated with trypsin (3) in rhe BLM-
enriched fraction. Abbreviations are: Vo, void volume; Vt, total
volume; I to 5, molecular weight marker proteins as listed in Methods;
abscissa, number of fractions collected; ordinates, nanomoles of S-2266
hydrolyzed (0—0, •—•, X—X) and absorption at 280 nm (---).
Fig. 6C). Peak 2 appeared in the same position as urinary
kallikrein corresponding to a molecular weight of about 4 x l0.
The activated prekallikrein (peak 3) had a higher molecular
weight, 1.5 x JO5 which is similar to that of prekallikrein shown
in Figure 6B. When the high molecular weight kallikrein ob-
tained by gel filtration was subjected to preparative polyacryl-
amide gel electrophoresis, it migrated with an Rf of 0.3, slower
than the other renal or urinary kallikrein (Rf = 1) [17]. The
trypsin-activated prekallikrein in peaks I and 3 and kallikrein in
peak 2 were inhibited by both antiserum to rat urinary kallikrein
and aprotinin at the same concentration as urinary or PM
kallikrein. In additional studies, identical results were obtained
when kininogenase activity was measured instead of S-2266
hydrolysis, and the molecular weights were determined on a
Biogel P 200 column instead of the Sephadex G-200.
Isoelectric focusing. As shown in Figure 7A the isoelectric
point of active BLM kallikrein was at pH 3.8 to 4.0 which is the
same as that of PM kallikrein. After the protein fractions were
eluted from the gel and treated with trypsin, activated prekalli-
krein was found almost at the same position as active BLM
kallikrein (Fig. 7B). Kallikrein activity (1 + 2 in Fig. 7B)
apparently increased by trypsin, compared with the untreated
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Fig. 5. Preparative gel electrophoresis of A active kallikrein (Rf = I)
and B prekallikrein of the BLM enriched fraction activated with
Sepharose-trypsin (Rf = 0.3) Abscissa represents the relative distance
of migration. Ordinate represents milliunits of S-2266 hydrolyzed.
Tube no.
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Fig. 7. Isoelectric focusing of active kallikrein on polyacrylamide gels
(A, B, and C; 2), prekallikrein (B, I), and prekallikrein after activation
by trypsin (C, 3). Abscissa represents number of gel slices. Ordinates
represent nanograms of bradykinin released and the pH gradient.
fraction (2 in Fig. 7A), indicating that the p1 of BLM prekalli-
krein was about the same as that of active BLM kallikrein.
However, when prekallikrein was activated first with Sepha-
rose-trypsin and then applied to the gel, two active kallikreins
were found with pis of 3.8 to 4.0 and 5.3 (Fig. 7C). The same p1
values were obtained when, in control experiments instead of
the 0.1% Triton, we used io— M melittin to solubilize kallikrein
and prekallikrein.
Renin activity. The isolated BLM-enriched fraction con-
tained renin activity as determined by radioimmunoassay of the
angiotensin I released. The activity found in the membrane
fraction was low, 13.3 1.3 ng angiotensin I released per hour
per milligram of protein, but this increased to 182 10/mg after
solubilization by Triton X-100 and centrifugation at x 105,000g.
Adding trypsin or plasmin to the membrane fraction or acidify-.
ing it to pH 3 did not enhance the activity of bound renin. Thus,
there was no evidence for the presence of a prorenin in the
fraction [26—28].
Discussion
We previously described a method for separation of a BLM-
enriched fraction from the homogenized rat kidney that con-
tained kallikrein and prekallikrein [19]. The native membrane-
bound enzyme had only a fraction of the activity of the soluble
enzyme. As summarized in Methods, the enrichment of the
fraction in BLM fragments was indicated by the increase in the
relative specific activity of Nat, KATPase and decrease in
a,
C
a,0,CC
C
alkaline phosphatase and glucose-6-phosphatase [19], by the
ratio of Nat, KATPase to Mg2 ATPase and by ultrastructur-
al studies on freeze fracture images [19]. Yamada et al [19]
showed with this technique of differential centrifugation that the
parathyroid hormone sensitive adenylate cyclase was enriched
about 80-fold and the calcitonin sensitive enzyme about 70-fold
in the fractions. K. Yamada (personal communication) also
raised antibodies to the BLM fraction in rabbit. In immunofluo-
rescence studies the antibodies reacted with the basal mem-
brane but not with the luminal membrane of rat tubules. By
using a different homogenization and centrifugation technique,
we also isolated a PM-enriched fraction mostly containing
active kallikrein called PM kallikrein [17, 18, 21]. PM kallikrein,
when released from the luminal membrane of the distal tubules,
could be the enzyme that appears in the urine.
We also found that the BLM-enriched fraction contains
kallikrein and prekallikrein which were solubilized by 0.1%
Triton X-100 and by a much lower concentration of the bee
venom peptide melittin [18]. Prekallikrein once solubilized is
activated by serine proteases such as plasmin or trypsin.
Trypsin in either free or in Sepharose-bound form activates
prekallikrein. Presumably, other endogeneous serine proteases
may also be activators of renal prekallikrein in vivo.
In addition, we found that the BLM fraction, even though it
was washed many times, still contained renin or a renin-like
enzyme, which became apparent after solubilization with a
detergent. Trypsin or acidification did not enhance the activity
indicating that the bound enzyme is not prorenin [26—28]. To
exclude the possibility that this finding was an artifact of
homogenization, we added membrane fractions to renin in
control studies in the supernatant of rat kidney homogenate, but
soluble renin was not adsorbed on the membrane-fraction.
Membrane-bound renin may be a form of renin retained by the
kidney.
In gel electrophoresis at an alkaline pH active kallikrein
solubilized from the BLM fraction migrated with the front, Rf =
1. Electrophoresis also indicated that BLM prekallikrein yields
a kallikrein which is different from other renal kallikreins
because of its slower migration rate (Rf = 0.3).
The results of the electrophoretic experiments were support-
ed by other findings. The activated BLM fraction contained two
kallikreins with different isoelectric points (p1 3.9 vs. 5.3) and
different molecular weights independent of whether Triton
(0.1%) or melittin (l0— M) was used for extraction.
In addition the apparent molecular weight of BLM prekalli-
krein was not altered upon activation by trypsin as shown by gel
filtration in a Sephadex G-200 column. The possibility of BLM
kallikrein forming a dimer during gel filtration, however, could
not be excluded. If this were true then the molecular weight of
the monomer would be in the range of 7 x l0 dalton. It should
be recalled here that the colon of monkey, dog, and man
contains a prekallikrein with a molecular weight higher than
that of normal tissue kallikrein (7 X 1O4 vs. 3 to 4 x l0 dalton),
which releases bradykinin instead of kallidin [22]. A recent
study by Zimmerman, Geiger, and Kortmann [29] stated that
this colon kallikrein crossreacts with antibody to urinary kalli-
krein. The BLM kallikrein also releases bradykinin instead of
kallidin and a conversion of kallidin to bradykinin was excluded
under the experimental conditions used. Other investigators
indicated recently that rat urinary kallikrein also releases brady-
4.0
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kinin [30] instead of kallidin, as other glandular and tissue
kallikreins do [31].
Membrane-bound kallikrein reacts poorly with antisera [17].
Without using urea the luminal rim of the tubular cells stained
most intensely with immunohistochemical techniques [321. In
another set of expçriments the apical membrane also stained
intensely [33], (although antigen was also found in both studies
in the cytosol) [32—34]. We found that after solubilization by a
detergent, kallikreins released from the membrane are inhibited
by antiserum to rat urinary kallikrein at the same dilution as
urinary kallikrein [17]. Thus, both PM and BLM kallikreins
share common antigenic determinants with urinary kallikrein.
The high molecular weight, the release of bradykinin, and the
lack of migration at pH 8.9 in electrophoresis are properties
shared by both plasma and BLM prekallikrein [35, 36]. Howev-
er, BLM kallikrein is inhibited by antiserum to urinary kalli-
krein and is not affected by soybean trypsin inhibitor, which
blocks plasma kallikrein activity [31]. Although trypsin has
been in use as an activator of prekallikrein for several decades,
it is possible that the activation of prekallikrein by trypsin does
not entirely mimic conditions in vivo, where renal prekallikrein
is activated presumably by a protease not yet characterized. If
this is true, then BLM prekallikrein activated in vivo may
resemble PM and urinary kallikrein more than the trypsin-
activated variety described here.
In conclusion, kallikrein in the ribosomes [14] of the tubular
cells could be coupled to carbohydrates in the Golgi apparatus
prior to release. Subsequently, it may be transported to the
inside membrane of lysosomal particles as suggested for the
rabbit kidney [37]. When these lysosomes fuse with the cell
membrane kallikrein becomes part of the outside cell mem-
brane. It is likely that kallikrein from the luminal side of the
membrane is released into the urine partly as active kallikrein
and partly as inactive prekallikrein. Data, obtained by measur-
ing kallikrein released within the kidney with a stop flow
technique [16], suggest that kallikreins originate from distal
tubular cells. Kallikrein from the basal membrane may appear
in renal lymph [3, 4] (C. P. Vio and N. A. Terragno, personal
communication) and venous effluent, where there is abundant
kininogen substrate. The final result would be the release of
kinins which would affect vascular resistance. Activation of a
prekallikrein by a serine protease also would be required for
expression of this function.
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